Garfield Greg Shaw 4
4 · NeuroPace Inc · Filed Apr 26, 2021
Insider Transaction Report
Form 4
NeuroPace IncNPCE
Garfield Greg Shaw
Director
Transactions
- Conversion
Common Stock
2021-04-26+5,595,493→ 5,614,384 total(indirect: See Footnote) - Conversion
Series A' Preferred Stock
2021-04-26−323,591→ 0 total(indirect: See Footnote)Exercise: $0.00→ Common Stock (324,450 underlying) - Conversion
Series A' Preferred Stock
2021-04-26−859→ 0 total(indirect: See Footnote)Exercise: $0.00→ Common Stock (859 underlying) - Conversion
Series B' Preferred Stock
2021-04-26−18,032→ 0 total(indirect: See Footnote)Exercise: $0.00→ Common Stock (18,032 underlying) - Conversion
Series B' Preferred Stock
2021-04-26−5,271,902→ 0 total(indirect: See Footnote)Exercise: $0.00→ Common Stock (5,271,902 underlying) - Conversion
Common Stock
2021-04-26+18,891→ 18,891 total(indirect: See Footnote)
Footnotes (3)
- [F1]Shares are held by the Greg and Dori Garfield Living Revocable Trust.
- [F2]KCK Ltd. has sole voting and investment power with respect to the shares. The board of directors of KCK Ltd., consisting of Antoine Sacy, Kamal Kassar, and Nael Karim Kassar, has delegated its authority to vote or invest the shares to Nael Karim Kassar. As such, Nael Karim Kassar may also be deemed to have sole voting and investment with respect to the shares. Mr. Kassar and Greg Garfield, who serves as Senior Managing Director with KCK-US, Inc., an affiliate of KCK Ltd., are also members of our board of directors.
- [F3]Each share of Preferred Stock automatically converted on a 1-for-1 basis into Common Stock upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Stock has no expiration date.